Navigation Links
Cequent to Provide Details at BIOCOM About Planned Launch of its Clinical Program - 3 p.m., Tuesday, October 27
Date:10/13/2009

CAMBRIDGE, Mass., Oct. 13 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Chief Executive Officer, Peter Parker, will provide details on Cequent's planned launch of its clinical program and highlight strategy and development goals in a company update scheduled for 3 p.m. on Tuesday, October 27, 2009, at the 2009 BIOCOM Investor Conference. The company has initiated a Series B round of financing; it is seeking to raise $15 million to take the company through Phase II clinical trials with its lead drug candidate.

Cequent is using the company's proprietary TransKingdom RNA interference (tkRNAi) technology to develop RNAi-based therapeutics - a new class of drugs designed to work by effectively deactivating the specific gene or genes implicated in the progression of a disease. The company has made considerable progress with its programs targeting polyposis and inflammatory bowel disease (IBD), demonstrating through in vivo testing and studies with non-human primates that its tkRNAi technology can silence target genes successfully. It expects to file its first IND (investigational new drug) application with the U.S. Food and Drug Administration for an orally administered tkRNAi drug targeting the primary oncogene in FAP (familial adenomatous polyposis) before the end of the quarter. FAP is a rare inherited gastrointestinal disease that causes hundreds to thousands of precancerous polyps to form in the colon, leading to colon cancer.

Cequent completed a $15 million Series A financing in June of 2007. Investors included Ampersand Ventures, Pappas Ventures, Yasuda, and the Novartis Option Fund.

2009 BIOCOM Investor Conference

The fourth annual BIOCOM Investor Conference takes place October 26 - 27, 2009, at the Hyatt Regency La Jolla, California. For more informat
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
2. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
3. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
4. Cequent Names Ted Hibben Chief Business Officer
5. Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases
6. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
7. CardioDynamics Provides 2007 Shareholder Meeting Update
8. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
9. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
10. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
11. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... CA (PRWEB) March 26, 2015 PRC ... (CRO), announced today several management and executive appointments effective ... Chief Financial Officer (CFO) and member of the Board ... of Business Operations, and Sue Dowden will assume the ... co-founder and current Chief Operations Officer (COO), has been ...
(Date:3/26/2015)... 26, 2015 The Market Element LLC, ... strategic alliance with Designing Gig LLC to provide website ... , “Forging this alliance with Designing Gig represents ... can extend a comprehensive, end-to-end, digital solution for our ... execution,” said Chuck Miller, president of The Market Element. ...
(Date:3/26/2015)... and CINCINNATI , March ... (LSE: SHP, NASDAQ: SHPG ) and Cincinnati ... broad research collaboration for rare diseases. The goal of ... therapies to treat rare diseases with high unmet ... with Cincinnati Children,s research expertise. As a nationally ...
(Date:3/26/2015)... BOSTON , March 26, 2015 /PRNewswire/ ... ), a global clinical research organization ... signed a definitive agreement to acquire all ... India ("QSI"), a leading provider of specialized ... refers to the collection, detection, assessment, monitoring, ...
Breaking Biology Technology:PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... showing unprecedented 89% reduction in risk of GIST relapse, with use of Gleevec after surgery ... ... ... Regulatory submissions reflect continued commitment to bringing new therapeutic ...
... August 27, Peakdale Molecular Ltd (CHAPEL-EN-LE-FRITH, UK) ... the pharmaceutical and,biotechnology industry, and ChemPrintCo LLC ... of products and systems for the biotechnology,industry, ... AssayReady4U(TM) is an online based storefront which ...
... Kavli Prize will be celebrated with a special ceremony that ... the seven Kavli laureates. Acclaimed scientists in the fields of ... , , Note: The award ceremony, lectures and symposia are open ... AM (CET), September 9, in Oslo Concert Hall prior to ...
Cached Biology Technology:Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 2Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 3Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 4Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 5Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 6Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 7Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 8Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 9Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 10Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 11Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 12Peakdale Molecular Launches AssayReady4U(TM) in Collaboration With ChemPrintCo LLC 2Peakdale Molecular Launches AssayReady4U(TM) in Collaboration With ChemPrintCo LLC 3Inaugural Kavli Prize ceremony and symposia: Sept. 8-11 (Oslo, Norway) 2Inaugural Kavli Prize ceremony and symposia: Sept. 8-11 (Oslo, Norway) 3
(Date:3/17/2015)...  MecklerMedia Corporation (OTCQX: MECK) announced its ... ever held in New York City ... 2015 at the Javits Convention Center. ... Acorn Product Development; Axis NJ; c-Link Systems; CoroWare; ... NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; RocketFarm ...
(Date:3/12/2015)... -- IriTech, a leading iris based identity management technology ... Design Network, announced today that the Chief Minister ... MK2120U device during a launching event of Andhra Pradesh ... The iris scanner is manufactured by U.S. based ... India through its Indian partner, Biometronic Technology, ...
(Date:3/12/2015)... -- Beta Systems today announced Fast ... (IAM) solution for a fixed price and with ... IAM package, customers benefit from the 30 years, ... implementations across different industries. The new fixed-price IAM ... necessary services and consulting. It spans the implementation ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... experts on biodiversity will gather from the 21th to the ... the transfer of biodiversity knowledge from the scientific community into ... in a project funded by the European Commission: " BiodiversityKnowledge ... practitioners to help all actors in the field of biodiversity ...
... Exercise clears the mind. It gets the blood pumping ... is familiar territory, but Dartmouth,s David Bucci thinks there ... several years there have been data suggesting that neurobiological ... work here," says Bucci, an associate professor in the ...
... Scientists at Queen Mary, University of London have ... underlying causes of psychiatric disorders. The study, published ... found zebrafish can modify their behaviour in response to ... School of Biological and Chemical Sciences who led the ...
Cached Biology News:A network of knowledge on biodiversity and ecosystem services in Europe 2Dartmouth researchers are learning how exercise affects the brain 2Dartmouth researchers are learning how exercise affects the brain 3Zebrafish could hold the key to understanding psychiatric disorders 2
... The CHEMICON MDR1 Shift Assay provides a convenient ... occur upon transport of MDR1 substrates. Thus, the ... to which small molecules act as transport substrates ... in the presence of MDR1 substrates, the MDR1 ...
... Kit is a simple high performance method ... Removes detergents without significant dilution of protein ... on the Detergent-OUT Spin column and collect ... column is suitable for removing detergents from ...
... The wide and long ... of Polaroid gel documentation systems. ... holds the camera in place ... that allows photography on the ...
... microarrays are derived from Paraffin embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
Biology Products: